2024 USCAST Virtual Public Meeting
USCAST is excited to announce that our 2024 virtual meeting will take place on Thursday, December 5, 2024 from 1:00 to 4:30 PM, EST. At this meeting, USCAST members will present proposed in vitro susceptibility test interpretive criteria (STIC, also known as susceptibility breakpoints) for ceftriaxone and azithromycin against Neisseria gonorrhoeae, trimethoprim-sulfamethoxazole for uncomplicated urinary tract infections due to Enterobacterales, and for oral cephalosporins (cephalexin, cefuroxime, and cefpodoxime) against Escherichia coli and Staphylococcus aureus.
Registration for the virtual meeting is free and can be completed using the link below. We encourage feedback on the proposed STIC from the community either during the meeting or afterwards in the open comment period that will last 60 days. Feedback from interested parties is critical in the setting of STIC. Final STIC recommendations will be based on objective consideration of any feedback received.
2024 Meeting Registration
In 2023, USCAST developed in vitro susceptibility test interpretive criteria (STIC, also known as susceptibility breakpoints) for the following clinical scenarios: 1) piperacillin/tazobactam against Enterobacterales and Pseudomonas aeruginosa; 2) amikacin, ceftazidime, ciprofloxacin, and minocycline against Acinetobacter baumannii; and 3) aminoglycosides against Enterobacterales and P. aeruginosa. Recordings from our virtual meeting can be found below and our updated breakpoints table can be found here.
Piperacillin/Tazobactam Breakpoints: Enterobacterales and P. aeruginosa
Thomas Lodise, PharmD
Executive Committee, USCAST